Philippines Business News API

{
    "totalArticles": 308432,
    "articles": [
        {
            "id": "792dc25090a08db5abf35029d535a901",
            "title": "Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines",
            "description": "Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1...",
            "content": "Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound.\nQ1 2026 EPS increased by 170% to $8.26 on a reported basis and increased by 156% to $8.55 on a ... [16273 chars]",
            "url": "https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines-302758113.html",
            "image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "publishedAt": "2026-04-30T10:45:00Z",
            "lang": "en",
            "source": {
                "id": "4e4307a07d2ce1e31acaf932954d3dd9",
                "name": "PR Newswire",
                "url": "https://www.prnewswire.com"
            }
        },
        {
            "id": "060d14dd4f2a29d28788a28b052c77aa",
            "title": "Bombardier Raises Free Cash Flow Guidance on Sharp Q1 2026 Increase, Records Strong Backlog Growth in Exceptional Quarter",
            "description": "Bombardier Raises Free Cash Flow Guidance on Sharp Q1 2026 Increase, Records Strong Backlog Growth in Exceptional Quarter",
            "content": "Revenues grew 5% year-over-year to $1.6 billion, including a remarkable 25% year-over-year gain from Services to $617 million.\nAdjusted EBITDA(1) reached $246 million, reflecting a 1% year‑over‑year decrease, with an adjusted EBITDA margin(2) of 15.4... [33178 chars]",
            "url": "https://bombardier.com/en/media/news/bombardier-raises-free-cash-flow-guidance-sharp-q1-2026-increase-records-strong-backlog",
            "image": "https://bombardier.com/sites/default/files/2025-03/og-image.jpg",
            "publishedAt": "2026-04-30T10:31:41Z",
            "lang": "en",
            "source": {
                "id": "33c502d3c754584afb5e1c1f3479fcd5",
                "name": "Bombardier",
                "url": "https://bombardier.com"
            }
        },
        {
            "id": "25adec9bdbdd75b29738f7ade9399ef0",
            "title": "Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones",
            "description": "Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX 1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million WINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX) Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX) GAAP Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of Cidara Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive Results From Phase 3 CORALreef AddOn Trial Received U.S. FDA Approval for IDVYNSO, a Once-Daily, Oral Treatment for Certain Adults With Virologically Suppressed HIV-1 Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology Pipeline Announced Agreement To Acquire Terns",
            "content": "Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2026.\n“We are moving with speed to transform our portfolio to one with a diversified set o... [27826 chars]",
            "url": "https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones/",
            "image": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20260430995314r1&sid=q4-prod&distro=nx&lang=en",
            "publishedAt": "2026-04-30T10:30:00Z",
            "lang": "en",
            "source": {
                "id": "8c57c2550cbba3c93432a0a7487b8d50",
                "name": "Merck.com",
                "url": "https://www.merck.com"
            }
        }
    ]
}